Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of UT-15C in pulmonary arterial hypertension
2012-000098-21Phase 3Unknown
- Sponsor
- United Therapeutics Corporation
- Start
- Aug 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Primary endpoint: Clinical assessments - Efficacy and Safety. Status: unknown.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2012-000098-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000098-21.